Second Sight Medical Products, Inc. (EYES): Price and Financial Metrics
EYES Price/Volume Stats
|Current price||$4.14||52-week high||$12.72|
|Prev. close||$4.36||52-week low||$3.42|
|Day high||$4.35||Avg. volume||132,982|
|50-day MA||$5.84||Dividend yield||N/A|
|200-day MA||$5.22||Market Cap||54.38M|
EYES Stock Price Chart Interactive Chart >
Second Sight Medical Products, Inc. (EYES) Company Bio
Second Sight Medical Products develops, manufactures, and markets implantable prosthetic devices to restore functional vision to blind patients in the United States, Canada, Europe, and Saudi Arabia. The company was founded in 1998 and is based in Sylmar, California.
EYES Latest News Stream
|Loading, please wait...|
EYES Latest Social Stream
View Full EYES Social Stream
Latest EYES News From Around the Web
Below are the latest news stories about SECOND SIGHT MEDICAL PRODUCTS INC that investors may wish to consider to help them evaluate EYES as an investment opportunity.
We're starting the final day of trading this week with a look at the biggest pre-market stock movers for Friday and what's moving them!
Second Sight Medical Products, Inc. Announces Shareholder Approval for Proposed Merger with Nano Precision Medical, Inc. and other Results of 2022 Annual Meeting
LOS ANGELES, July 29, 2022--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held on July 27, 2022, where the quorum was present. The formal results of the vote are included in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission.
LOS ANGELES, July 18, 2022--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prostheses that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company received notice from the National Institutes of Health ("NIH") of the release of year four funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (the "Orion Trial"), grant 5UH3NS103442.
Nano Precision Medical Co-Founder and CEO Discusses Proposed Second Sight Merger in Interview to Air on Bloomberg U.S. on the RedChip Money Report®
LOS ANGELES, April 14, 2022--Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight"), a recognized global leader in neuromodulation devices for blindness, today announced that an interview with Adam Mendelsohn, Ph.D., Co-Founder and CEO of Nano Precision Medical, Inc. ("NPM"), will air on The RedChip Money Report® on Bloomberg US on April 16 at 7 p.m. Eastern Time (ET). Bloomberg US is available in an estimated 73 million homes across the United States.
Second Sight Medical (NASDAQ:EYES) stock is up 15% this morning after announcing a merger with Nano Precision. Source: Shutterstock So what do you need to know? To start, Second Sight Medical is acquiring Nano Precision through an all-stock deal. As part of this, it will issue 134 million shares. Current EYES stock holders will own roughly 23% of the combined company. Right now, Second Sight expects the deal to close by the end of the third quarter. Before it does, it will be subject to stockhol
EYES Price Returns
Continue Researching EYESWant to see what other sources are saying about Second Sight Medical Products Inc's financials and stock price? Try the links below:
Second Sight Medical Products Inc (EYES) Stock Price | Nasdaq
Second Sight Medical Products Inc (EYES) Stock Quote, History and News - Yahoo Finance
Second Sight Medical Products Inc (EYES) Stock Price and Basic Information | MarketWatch